Cara Anne Schuck, ATC | |
5157 Main St, Suite 200, Downers Grove, IL 60515-4616 | |
(630) 435-6461 | |
Not Available |
Full Name | Cara Anne Schuck |
---|---|
Gender | Female |
Speciality | Specialist/technologist - Athletic Trainer |
Location | 5157 Main St, Downers Grove, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104170299 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111NR0400X | Chiropractor - Rehabilitation | 096.003367 (Illinois) | Secondary |
2255A2300X | Specialist/technologist - Athletic Trainer | 096.003367 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Cara Anne Schuck, ATC 2280 Hassell Rd Apt 105, Hoffman Estates, IL 60169-2105 Ph: (630) 487-7861 | Cara Anne Schuck, ATC 5157 Main St, Suite 200, Downers Grove, IL 60515-4616 Ph: (630) 435-6461 |
News Archive
High schools throughout Southeastern Pennsylvania are invited to join Shire's The Great Food Fight!, the first regional student food drive to fight hunger. The goal: to collect 25 tons of food - the equivalent of 50,000 meals - for Philabundance and the thousands of local families who rely on the food services they provide. Shire will present the school that collects the most food per student a grand prize of $10,000.
More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
Can optimism be ethically problematic? Yes, according to a new study, which found unrealistic optimism prevalent among participants in early-phase cancer trials and suggested that it may compromise informed consent.
Use of electronic health records by hospitals across the United States has had only a limited effect on improving the quality of medical care, according to a new RAND Corporation study.
Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release tablets 100mg and 200mg. Distribution of the product will commence immediately.
› Verified 5 days ago